Parthenolide accelerates diabetic wound healing through the STAT3 and TNF-α/NF-kappaB pathways Authors: Dan Song, Zhuo Zeng, Hui Tang, Kaiqi Chen, JiaMin Li, Yi Liang, Xia Lei, Hong Liu Published: 2026 ABSTRACT Diabetic wounds, a common complication of diabetes, can elicit intricate inflammatory responses and progressive tissue damage without proper treatment. Parthenolide (PTL), a natural compound isolated from the medicinal plant feverfew (Tanacetum balsamita), possesses antitumor, anti-inflammatory, and antioxidant properties. This study seeks to elucidate the molecular mechanisms by which PTL promotes diabetic wound healing. Using network pharmacology and molecular docking, we identified TNF-α and STAT3 as potential targets of PTL. In diabetic mouse models, PTL promoted wound healing with a distinct dose-dependent effect. Both 100 µM and 200 µM PTL significantly accelerated mouse wound repair, while 50 µM PTL failed to exert stable therapeutic effects, likely due to insufficient concentration. Histological and immunological staining assays confirmed that PTL promoted wound healing by enhancing keratinocyte proliferation, angiogenesis, and the conversion of macrophages to the M2 type. Furthermore, in vitro experiments were carried out by stimulating RAW264.7 macrophages with LPS. Through CCK-8 assays, immunofluorescence staining, and Western blotting, we further demonstrated that PTL might modulate the STAT3 and TNF-α/NF-κB signalling pathways, as well as regulate phenotypic switching of macrophages in the inflammatory microenvironment. Collectively, PTL promotes wound healing in diabetic conditions, a mechanism that may be mediated by the regulation of the STAT3 and TNF-α/NF-κB signalling pathways and the facilitation of macrophage phenotypic switching to the M2 phenotype to modulate wound-site inflammatory responses. Thus, PTL emerges as a potential therapeutic candidate for improving the healing of diabetic wounds.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00210-026-05417-3. Introduction Diabetic wounds are chronic, non-healing lesions arising from diabetes-induced impairment of cutaneous tissue repair and constitute one of the most frequent complications in individuals with diabetes. It is estimated that approximately 18.6 million people worldwide develop diabetic wounds each year Armstrong et al. (2023). In the absence of timely and appropriate intervention, these refractory lesions can lead to devastating consequences, including gangrene, sepsis, limb amputation, and even death. Notably, the 5-year mortality rate associated with diabetic foot ulcers exceeds that of several malignancies, underscoring their status as a major global public health challenge Jiang et al. (2023). Diabetic wound healing impairment is primarily driven by a chronic inflammatory microenvironment resulting from persistent hyperglycemia and its complications Chen et al. (2022). In diabetes, wound susceptibility is heightened via pathological factors including ischemia, neuropathy, microbial dysbiosis, and impaired skin architecture, leading to exacerbated and sustained chronic inflammation Wang et al. (2025). At the molecular level, hyperglycemia induces significant oxidative stress at the wound site, disrupting chemokine gradients and compromising immune cell recruitment. This oxidative stress, together with aberrant MMP overexpression and disrupted collagen degradation, traps wounds in a prolonged inflammatory phase Mohsin et al. (2024). In addition, hyperglycemia can disrupt the switching of macrophage phenotypes, leading to a sustained predominance of M1 macrophages that perpetuates chronic inflammation and impedes tissue repair Liu et al. (2020). Therefore, strategies aimed at modulating this dysregulated inflammatory response represent a potential therapeutic candidate for diabetic wound healing. Although a tightly regulated inflammatory response is essential for the recognition and clearance of invading pathogens, dysregulated or excessive inflammation leads to the production of bioactive mediators that damage tissues and hinder wound closure Lv et al. (2023). Consequently, fine-tuning the inflammatory response has emerged as a particularly potential therapeutic candidate for the management of diabetic wounds. Parthenolide (PTL) is a natural compound isolated from chrysanthemum flowers of the Asteraceae family. Contemporary pharmacological studies have revealed its diverse bioactivities, including anti-inflammatory, immunosuppressive, antioxidant, and anticancer effects Zhan et al. (2024). Chrysanthemum has a long-standing history of medicinal use in China, tracing back to the Ming and Qing dynasties. Its imperial distinction was conferred during the Qianlong reign of the Qing dynasty, when it was honored with the title “Divine Chrysanthemum of Wulin” following its documented use in a decoction that successfully alleviated the Empress’s wind-cold syndrome. According to the Divine Farmer’s Classic of Materia Medica, chrysanthemum is credited with promoting blood circulation, imparting bodily lightness, and prolonging longevity with prolonged consumption. These attributes are further elaborated in the Compendium of Materia Medica, which highlights its efficacy in dispelling wind-heat, nourishing the liver, and replenishing Yin essence Liu et al. (2024). Researchers from the School of Pharmacy at Yanbian University demonstrated that PTL attenuated hepatic inflammation and fibrosis by modulating crosstalk between the TLR4 and STAT3 signaling pathways Cui et al. (2021). In addition, investigators from the Department of Gastroenterology at Xinqiao Hospital confirmed that PTL mitigated colonic inflammation by rebalancing the Treg/Th17 axis via regulation of the gut microbiota Liu et al. (2020). Thus, the anti-inflammatory efficacy of PTL is well substantiated by both modern pharmacology and the theoretical framework of traditional Chinese medicine. Nonetheless, its therapeutic potential in the context of diabetic wound healing remains largely unexplored. On the basis of this dual body of evidence, we posit that PTL may promote the repair of diabetic wounds by modulating inflammatory responses. Accordingly, this study first employed network pharmacology approaches to elucidate the potential pharmacological mechanisms of PTL in the treatment of diabetic wounds. The therapeutic efficacy of PTL was then evaluated in vivo using streptozotocin (STZ)-induced diabetic mouse models and in vitro using LPS-stimulated RAW264.7 macrophages. This integrated strategy clarified the effects of PTL on diabetic wound repair and macrophage phenotype transitions, thereby providing a foundation for future mechanistic investigations and clinical translation of PTL in the management of diabetic wound healing. Materials and methods Network pharmacology analysis The candidate ingredients and corresponding targets of PTL were initially collected from the TCMSP database (https://www.tcmspw.com.) and the TCMIP database (http://www.tcmip.cn/TCMIP/index.php/Home/Login/login.html.). The preliminary screening of PTL ingredients was performed according to the following criteria: drug-likeness (DL) > 0.18, half-life (HL) > 4 h, and topological polar surface area (TPSA) < 140. Furthermore, potential targets of PTL were predicted using the SwissTargetPrediction platform, yielding a total of 254 candidate targets. The UniProt database (https://www.uniprot.org/) was used to standardize gene names, remove duplicate entries and non-human genes, and obtain the final candidate target genes for PTL. Diabetic wound-related genes were retrieved from the GeneCards database and supplemented by the OMIM database using the keyword “diabetic wound,” resulting in 7507 disease-related targets. A Venn diagram was constructed to identify the intersection of PTL candidate targets and diabetic wound-related targets, and 218 common targets were obtained as key potential targets for subsequent analysis. PPI network construction The above 218 overlapping genes were uploaded to the STRING database to construct a protein–protein interaction (PPI) network. On the STRING platform, “Homo sapiens” was selected as the organism, the confidence score was set to 0.4, and isolated nodes were removed. The generated PPI network contained 207 nodes and 5746 edges. Network analysis and hub gene identification The results from STRING were imported into Cytoscape software (v3.9.1) for visualization analysis. The Network Analyzer plugin of Cytoscape was used to calculate network parameters, including a clustering coefficient of 0.553. The screening of key targets was mainly based on the topological characteristics of nodes, including degree, betweenness centrality, closeness centrality, and edge count. The top 20 nodes with the highest degree values were identified as potential key targets. Furthermore, the CytoHubba plugin of Cytoscape was used to identify the top 10 hub genes from the PPI network, such as TNF-α, Stat3, Casp3, and Akt. In addition, the Metascape database was used for Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Terms with P < 0.01 and an enrichment score > 1.5 were regarded as statistically significant. GO and KEGG results were presented as bubble plots. All data analyses and visualizations were performed using custom scripts written in R and Python. Molecular docking The 2D structure file of PTL was obtained from the PubChem database. Chem3D software (v20.0) was used to optimize the structure of PTL. The 3D structures of the target proteins were obtained from the RCSB PDB (Research Collaboratory for Structural Bioinformatics Protein Data Bank). Water molecules and residues were removed from the protein structures using PyMOL software (v2.2.0). To predict the active pockets of STAT3 and TNF-α, the protein structure was analyzed using the DeepSite and DoGSiteScorer servers to obtain the coordinates of active sites. Finally, molecular docking conduction was performed using AutoDock Vina software (v1.1.2). The results were subsequently presented by PyMOL software (v2.2.0) and LigPlot + (v2.2.8). Establishment of mouse diabetic wound models C57BL/6 J male mice were purchased from Beijing Viton Lihua Laboratory Animal Technology Co., Ltd (Beijing, China). After 1 week of acclimatization feeding, mice were randomly assigned to four groups: control group (0, n = 5), 50 µM PTL-treated group (50 µM, n = 5), 100 µM PTL-treated group (100 µM, n = 5), and 200 µM PTL-treated group (200 µM, n = 5). Subsequently, each C57BL/6 J mouse was injected intraperitoneally with STZ (60256ES76, Yeasen, China) once at a dose of 150 mg/kg. The preparation was carried out under dark conditions in an ice bath, and all injections were completed within 30 min. Subsequently, after 72 h, blood samples were collected from the tail vein using a glucometer (Yuwell, China). The diabetic wound models were considered successfully established when blood glucose concentrations reached ≥ 16.7 mmol/L (Mu et al. 2025; Wu et al. 2024). The backs were shaved by anesthetizing the animals with pentobarbital sodium (50 mg/kg). Next, the backs were cleaned with 75% medical alcohol, and then, a single circular full‑thickness skin defect with a diameter of 6 mm was created on the back using a biopsy punch, extending to the subcutaneous tissue to establish a full‑thickness skin wound model. All animal experiments were conducted in full compliance with the ARRIVE guidelines. Animals were randomly assigned to experimental groups, and investigators were blinded during model establishment, data collection, and statistical analysis to reduce selection and detection bias. The study was approved by the Ethics Committee of the Army Specialty Medical Center (approval number: AMUWEC20257032). Drug treatment After the diabetic mouse model was established, mice were randomly allocated to different groups. Then, 0.1 mL of PTL at various concentrations (0, 50 µM, 100 µM, 200 µM) was injected into the wound margins daily. Wound healing was evaluated on days 3, 6, and 9 by researchers who were blinded to the group assignments. High-resolution images of the wounds were taken during the experiment and the wound area was measured using ImageJ software. The percentage of wound closure was calculated as (initial wound area—actual wound area)/initial wound area × 100%. The initial wound area represented the maximum wound area. The groups were treated continuously for 14 days and then sampled. Hematoxylin–eosin (H&E) staining Skin wound tissues were fixed in 4% paraformaldehyde (PMK0240, bioprimacy, China) and embedded in paraffin. Hematoxylin–eosin (H&E) staining was performed according to standard procedures. Images were taken using a light microscope (Nikon, Japan). Immunohistochemical staining Deparaffinized sections of wound tissue were antigenically repaired with EDTA buffer (G1203, Servicebio, China). After blocking with serum, primary antibodies were incubated overnight at 4 °C and then stained with the corresponding secondary antibodies. Images were captured with a microscope (Olympus, Japan) and analyzed using ImageJ software. The following primary antibodies were used: Ki67 (NB110—89,717, Novus Biologicals, USA), CD31 (28,083—1-AP, Proteintech, China), and the following secondary antibodies were used: goat anti-rabbit IgG (SA00004—2, Proteintech, China) or goat anti-mouse IgG (SA00001—1, Proteintech, China). Immunofluorescence staining Wound tissue samples were dehydrated and embedded in paraffin. The sections were washed and then stained at 4 °C overnight with the primary antibodies. Then, they were stained with the corresponding HRP-conjugated secondary antibodies, and the nuclei were stained by adding DAPI dye solution containing a fluorescence quencher (P0131, Beyotime, China). Finally, the membranes were blocked and then visualized with a light microscope (Olympus, Japan). The following primary antibodies were used: CD68 (66,231—2-Ig, Proteintech, China), CD163 (16,646—1-AP, Proteintech, China), CD206 (ET1702—04, HUABIO, China). The following secondary antibodies were used: Alexa Fluor 594-conjugated Goat Anti-Rabbit IgG (H + L) (111—585—003, Jackson, China), Alexa Fluor 488-conjugated Goat Anti-Rabbit IgG (H + L) (GB25303, Servicebio, China), or Alexa Fluor 488-conjugated Goat Anti-Mouse IgG (H + L) (GB25301, Servicebio, China). Cell culture and manipulation RAW264.7 macrophages were purchased from the National Biomedical Testing Laboratory Cell Resource Bank (CX0022, Boster, China). A total of 10% fetal bovine serum (10,438,018, Gibco, USA) and 1% penicillin/streptomycin were added to cells under culture conditions of 37 °C and 5% CO2. RAW264.7 macrophages were treated with 0.5 µg/mL LPS (L4391, Sigma, USA) and various concentrations of PTL (IP0090, Solarbio, China) for 24 h. Cell viability assay RAW264.7 macrophages were inoculated in 96-well plates and cultured in 10% fetal bovine serum for 24 h. The original medium was then replaced with fresh medium supplemented with different concentrations of PTL (0, 2.5, 5, 10, 20 µM), respectively. Cell viability was assessed using the Cell Counting Kit-8 (BG0025, Baoguang Bio, Chongqing, China) assay. Absorbance at 450 nm was measured using the Enzyme-Linked Immunosorbent Assay Reader (Thermo Fisher, America). Western blot Protein extracts from RAW264.7 macrophages treated with LPS and different concentrations of PTL (5 and 10 µM) were analyzed by Western blot. Briefly, samples were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE, Servicebio, Wuhan, China). The proteins were transferred to PVDF membranes, blocked in fast blocking buffer (PS108P, Epizyme, China), and incubated with primary antibodies overnight. This was followed by a 2—h incubation with the corresponding secondary antibody. The protein bands were detected using Femto-Sensitive ECL Solution (ECL-0100, SmartBuffers, China), and the intensity of the bands was quantified using Image software (Bio-Rad). The following primary antibodies were used: NF-κb (A27463, ABclonal, China), TNF-α (A11534, ABclonal, China), STAT3 (A1192, ABclonal, China), p-STAT3 (AP0705, ABclonal, China), and β-actin (20,536—1-AP, Proteintech, China), using the following secondary antibodies: goat-anti-rabbit IgG (SA00001—2, Proteintech, China) or goat-anti-mouse IgG (SA00001—1, Proteintech, China). Statistical analysis The Student’s t-test was conducted to compare variables between two groups, while the one-way ANOVA followed by Tukey’s post-hoc test was used to compare variables among three or more groups. Prior to parametric analysis, data normality was assessed. All data represent biological replicates obtained from independent mice. All data were analyzed using GraphPad Prism 9.0. Values are expressed as mean ± standard error of the mean (SEM). P < 0.05 was considered statistically significant. Results Network pharmacology analysis and molecular docking results of PTL In this study, we first explored the potential association between PTL and diabetic wounds using a network pharmacology approach. The 2D structure of PTL was obtained (Fig. 1A), and 254 putative protein targets of PTL were retrieved from the TCMSP and TCMIP databases. These targets were then intersected with diabetic wound–related disease targets (Fig. 1B). A total of 218 overlapping genes were imported into the STRING database for protein–protein interaction (PPI) analysis, and a target–pathway network linking PTL to diabetic wound–associated targets was constructed (Fig. 1C). From this network, the ten genes with the highest degree values were identified and selected as core targets (Fig. 1D).Fig. 1Network pharmacology analysis and molecular docking results of PTL. A The molecular structure of PTL. B Venn diagram of PTL and diabetic wound. C PPI network diagram of common targets. D Degree of the top ten common targets (number of node-connected edges) of common targets in the PPI network. E KEGG pathway enrichment. F Gene ontology (GO) analysis. G, H Molecular docking score of the top ten common targets. I, J Molecular docking–predicted binding mode. Molecular docking of PTL with I TNF-α and J STAT3 Network pharmacology analysis and molecular docking results of PTL. A The molecular structure of PTL. B Venn diagram of PTL and diabetic wound. C PPI network diagram of common targets. D Degree of the top ten common targets (number of node-connected edges) of common targets in the PPI network. E KEGG pathway enrichment. F Gene ontology (GO) analysis. G, H Molecular docking score of the top ten common targets. I, J Molecular docking–predicted binding mode. Molecular docking of PTL with I TNF-α and J STAT3 To further elucidate the mechanism by which PTL ameliorates diabetic wounds, GO and KEGG enrichment analyses were performed. These analyses revealed that the enriched signaling pathways were closely associated with diabetic wound pathology, including those related to lipid metabolism, viral infection, inflammatory responses, and other relevant pathways (Fig. 1E and F). Molecular docking simulation was performed to predict the potential binding modes of PTL with core target proteins. Docking scores and pathway mapping were used to analyze the putative ligand–target relationships, and the potential protein–ligand interactions were preliminarily evaluated based on structural and energetic properties (Fig. 1G and H). Combined with GO and KEGG enrichment analyses, the docking results suggested that TNF-α and STAT3 may represent potential candidate targets of PTL, which were further visualized using PyMOL (Fig. 1I and J). These in silico predictions provide a hypothetical framework supporting that PTL may contribute to diabetic wound healing, potentially through the regulation of TNF-α and STAT3. PTL accelerates diabetic wound healing The therapeutic efficacy of PTL on diabetic wounds was further evaluated in STZ-induced diabetic mice (n = 5). A total of 0.1 mL PTL at varying concentrations (0, 50 µM, 100 µM, 200 µM) was injected daily around the wound margins, and wound closure was assessed on days 3, 6, and 9 (Fig. 2A and B). The results demonstrated that both 100 µM and 200 µM PTL markedly enhanced diabetic wound healing. Notably, on day 3 post-injury, the wound closure rate in the 100 µM group was higher than that of the control group (Fig. 2C). Moreover, compared with the control group, the 100 µM and 200 µM PTL groups continued to exhibit significantly accelerated wound closure on days 6 and 9 (Fig. 2D and E). Although a trend toward improved healing was observed in the 50 µM group, the difference did not reach statistical significance, likely because this lower concentration was insufficient to elicit a robust and sustained pro-healing effect in diabetic wounds.Fig. 2PTL accelerates diabetic wound healing. A Images of wound healing in different groups at day 0, day 3, day 6, and day 9. B Quantitative analysis of wound area percentage in different groups at day 0, day 3, day 6, and day 9. Wound healing rate in different groups at C day 3, D day 6, and E day 9. Data are presented as mean ± SD (n = 5). ∗ P < 0.05, ∗ ∗ P < 0.01 PTL accelerates diabetic wound healing. A Images of wound healing in different groups at day 0, day 3, day 6, and day 9. B Quantitative analysis of wound area percentage in different groups at day 0, day 3, day 6, and day 9. Wound healing rate in different groups at C day 3, D day 6, and E day 9. Data are presented as mean ± SD (n = 5). ∗ P < 0.05, ∗ ∗ P < 0.01 PTL reduces inflammation and accelerates re-epithelialization in diabetic wound Histological evaluation of H&E-stained sections was performed to assess the effects of PTL on granulation tissue formation and re-epithelialization during wound repair (Fig. 3A). Randomly selected tissue samples were used for histological acute inflammation scoring (HAIS). With respect to inflammatory changes in granulation tissue, the acute inflammation scores in the 100 µM and 200 µM PTL groups were significantly reduced on day 3 (Fig. 3B) (P < 0.05). Re-epithelialization of the wound surface was also examined (Fig. 3C). On day 3, H&E-stained sections showed that the epithelial tongue length in the 100 µM PTL-treated group was longer than that in the control group (Fig. 3D). By day 6, this difference was further enhanced (Fig. 3E). Collectively, these findings indicate that both 100 µM and 200 µM PTL effectively accelerate wound healing by attenuating inflammation and promoting re-epithelialization.Fig. 3PTL reduces inflammation and accelerates re-epithelialization in diabetic wound. A Representative H&E staining of wound samples in different groups at day 3 and day 6. Scale bar = 200 µM, scale bar = 50 µM. B Quantitative analysis of histological scores in different groups at day 0, day 3, day 6, and day 9. C Quantitative analysis of the length of neo-epithelium in wound. Quantitative analysis of the relative length of neo-epithelium in wound at D day 3 and E day 6. Data are presented as mean ± SD (n = 5). ∗ ∗ P < 0.01 PTL reduces inflammation and accelerates re-epithelialization in diabetic wound. A Representative H&E staining of wound samples in different groups at day 3 and day 6. Scale bar = 200 µM, scale bar = 50 µM. B Quantitative analysis of histological scores in different groups at day 0, day 3, day 6, and day 9. C Quantitative analysis of the length of neo-epithelium in wound. Quantitative analysis of the relative length of neo-epithelium in wound at D day 3 and E day 6. Data are presented as mean ± SD (n = 5). ∗ ∗ P < 0.01 PTL promotes keratinocyte proliferation and neovascularization The reparative phase of wound healing encompasses multiple critical biological processes. In this study, we concentrated on two principal mechanisms: keratinocyte proliferation and neovascularization. The former is tightly associated with re-epithelialization, whereas the latter serves as a key indicator of granulation tissue remodeling. To assess these processes, immunohistochemical staining for Ki67 and CD31 was performed on wound tissues on day 3. Ki67 is a classical marker of cell proliferation, while CD31 is a well-established marker of neovascularization. Ki67 staining revealed that all three PTL concentrations enhanced keratinocyte proliferation, as evidenced by the abundant dark yellow nuclear granules in the basal layer of the nascent epidermis (Fig. 4A). The most pronounced pro-proliferative effect was observed in the 100 µM PTL group, in which the proliferation index was higher than that in the control group (Fig. 4B). Similarly, CD31 immunostaining demonstrated an increase in neovessel formation within the newly generated granulation tissue in the 100 µM group (Fig. 4C), with a higher CD31 expression intensity compared to the control group (Fig. 4D).Fig. 4PTL promotes keratinocyte proliferation and neovascularization. Immunostaining for A Ki67 and B CD31 in different groups at day 3. Scale bar = 200 µM, scale bar = 50 µM. C Quantitative analysis of the proliferation rate in different groups at day 3. D Quantitative analysis of the neovascularization rate at day 3. Data are presented as mean ± SD (n = 5). ∗ P < 0.05 PTL promotes keratinocyte proliferation and neovascularization. Immunostaining for A Ki67 and B CD31 in different groups at day 3. Scale bar = 200 µM, scale bar = 50 µM. C Quantitative analysis of the proliferation rate in different groups at day 3. D Quantitative analysis of the neovascularization rate at day 3. Data are presented as mean ± SD (n = 5). ∗ P < 0.05 PTL contributes to M2-phenotype transition in diabetic wound PTL is well recognized for its anti-inflammatory properties; however, whether it can modulate macrophage phenotype transitions in diabetic wounds has remained unclear. Our findings indicated that TNF-α and STAT3 were preferential binding targets of PTL, and both have been implicated in the regulation of macrophage polarization (Lin et al. 2021; Yang 2024). We therefore hypothesized that PTL might similarly promote the phenotypic switch of macrophages from a pro‑inflammatory (M1) to an anti‑inflammatory (M2) phenotype in diabetic wounds. To further substantiate this hypothesis, wound tissues were harvested from mice on day 6. Immunofluorescence co-staining for CD68 and CD163 was performed to evaluate the proportion of anti‑inflammatory macrophages within the wound macrophage population (Fig. 5A). Meanwhile, immunofluorescence co‑staining for CD68 and INOS was conducted to assess the percentage of pro‑inflammatory macrophages (Fig. 5B). The results revealed that 100 µM and 200 µM PTL resulted in abundant anti‑inflammatory macrophages, accompanied by a significant reduction in pro‑inflammatory macrophages. In contrast, no obvious enrichment of anti‑inflammatory macrophages was observed in the 50 µM treatment group or the control group (Fig. 5C–F). These observations preliminarily suggest that PTL accelerates wound repair, at least in part, by orchestrating macrophage phenotype transitions.Fig. 5PTL contributes to the M2-phenotype transition in diabetic wound. A Immunofluorescent staining of CD68 and CD163 in different groups at day 6. Green fluorescence indicates CD68, and red fluorescence indicates CD163. Scale bar = 20 µM. B Immunofluorescent staining of CD68 and INOS in different groups at day 6. Green fluorescence indicates CD68, and red fluorescence indicates INOS. Scale bar = 20 µM. C Quantitative analysis of the intensity of CD163 positive rate in different groups at day 6. D Quantitative analysis of the CD163/CD68 positive rate at day 6. Data are presented as mean ± SD. E Quantitative analysis of the intensity of INOS positive rate in different groups at day 6. F Quantitative analysis of the INOS/CD68 positive rate at day 6. Data are presented as mean ± SD (n = 5). ∗ ∗ P < 0.01 PTL contributes to the M2-phenotype transition in diabetic wound. A Immunofluorescent staining of CD68 and CD163 in different groups at day 6. Green fluorescence indicates CD68, and red fluorescence indicates CD163. Scale bar = 20 µM. B Immunofluorescent staining of CD68 and INOS in different groups at day 6. Green fluorescence indicates CD68, and red fluorescence indicates INOS. Scale bar = 20 µM. C Quantitative analysis of the intensity of CD163 positive rate in different groups at day 6. D Quantitative analysis of the CD163/CD68 positive rate at day 6. Data are presented as mean ± SD. E Quantitative analysis of the intensity of INOS positive rate in different groups at day 6. F Quantitative analysis of the INOS/CD68 positive rate at day 6. Data are presented as mean ± SD (n = 5). ∗ ∗ P < 0.01 PTL regulates TNF‑α/NF‑κB and STAT3 signaling and modulates macrophage phenotype transition in vitro In order to further verify our hypothesis, we first performed a CCK-8 assay to assess the effects of PTL on macrophage viability. The results showed that 2.5 µM, 5 µM, and 10 µM PTL did not adversely affect macrophage survival (Fig. 7A), and therefore, 5 µM and 10 µM were selected for subsequent experiments. The expression of cleaved caspase‑3, an apoptotic marker, was detected by Western blot. The results demonstrated no obvious change in cleaved caspase‑3 levels after PTL treatment, indicating that PTL does not exert its effects via inducing cell death (Figure S1). Immunofluorescence staining was then performed to analyze macrophage phenotypes. Our results showed that PTL promoted the phenotypic shift of macrophages toward an anti‑inflammatory phenotype (M2) and inhibited their shift toward a pro‑inflammatory phenotype (M1) under inflammatory conditions (Fig. 6A and B). In the 5 µM and 10 µM PTL‑treated groups, the fluorescence intensity of CD206 and the percentage of CD206‑highly positive macrophages were both significantly increased (Fig. 6C and D), whereas the fluorescence intensity of CD86 and the percentage of CD86‑highly positive macrophages were both significantly decreased (Fig. 6E and F). Besides, qRT‑PCR analysis showed that PTL treatment significantly upregulated the mRNA expression levels of M2 macrophage‑related markers, including IL‑10 and Arg‑1, while markedly reducing the mRNA expression of the M1 macrophage‑related marker IL‑1β (Figure S2). Western blot analysis further revealed that TNF-α and NF-κB expression levels were markedly reduced in PTL-treated macrophages compared with the LPS-only group (Fig. 7B), suggesting that PTL may regulate macrophage phenotype transition in an inflammatory microenvironment via the TNF-α/NF-κB axis (Fig. 7C and D). In addition, the Western blot results for STAT3 and p-STAT3 (Fig. 7B) showed that total STAT3 expression was elevated following LPS stimulation, whereas PTL treatment decreased STAT3 protein levels (Fig. 7E). Similarly, LPS promoted the phosphorylation of STAT3, while PTL treatment decreased the phosphorylation level of STAT3 (Fig. 7F). Collectively, these findings indicate that PTL promotes macrophage transition toward an anti-inflammatory phenotype (M2) under inflammatory conditions, likely through coordinated regulation of STAT3 expression and activation, together with modulation of the TNF-α/NF-κB signaling axis.Fig. 6PTL regulates the transition of RAW264.7 macrophages into the anti-inflammatory phenotype (M2). A Immunofluorescent staining of CD206 in different groups. Green fluorescence indicates CD206. Scale bar = 100 µM. B Immunofluorescent staining of CD86 in different groups. Green fluorescence indicates CD86. Scale bar = 100 µM. C Quantitative analysis of the intensity of CD206 positive rate in different groups. D Quantitative analysis of the CD206 positive rate. Data are presented as mean ± SD. E Quantitative analysis of the intensity of CD86 positive rate in different groups. F Quantitative analysis of the CD86 positive rate. Data are presented as mean ± SD (n = 3). ∗ P < 0.05, ∗ ∗ P < 0.01Fig. 7PTL regulates TNF‑α/NF‑κB and STAT3 signaling in vitro. A The CCK-8 test was used to determine the toxic effects of PTL on RAW264.7 macrophages. 2.5, 5, and 10 µM of PTL were nontoxic to macrophages (n = 3). B The protein levels of TNF-α, NF-κB, STAT3, and p-STAT3 expression by Western blotting on RAW264.7 macrophages. Quantitative analysis of the expression levels of C NF-κB, D TNF-α, E STAT3, and F p-STAT3. Data are presented as mean ± SD (n = 3). ∗ ∗ P < 0.01 PTL regulates the transition of RAW264.7 macrophages into the anti-inflammatory phenotype (M2). A Immunofluorescent staining of CD206 in different groups. Green fluorescence indicates CD206. Scale bar = 100 µM. B Immunofluorescent staining of CD86 in different groups. Green fluorescence indicates CD86. Scale bar = 100 µM. C Quantitative analysis of the intensity of CD206 positive rate in different groups. D Quantitative analysis of the CD206 positive rate. Data are presented as mean ± SD. E Quantitative analysis of the intensity of CD86 positive rate in different groups. F Quantitative analysis of the CD86 positive rate. Data are presented as mean ± SD (n = 3). ∗ P < 0.05, ∗ ∗ P < 0.01 PTL regulates TNF‑α/NF‑κB and STAT3 signaling in vitro. A The CCK-8 test was used to determine the toxic effects of PTL on RAW264.7 macrophages. 2.5, 5, and 10 µM of PTL were nontoxic to macrophages (n = 3). B The protein levels of TNF-α, NF-κB, STAT3, and p-STAT3 expression by Western blotting on RAW264.7 macrophages. Quantitative analysis of the expression levels of C NF-κB, D TNF-α, E STAT3, and F p-STAT3. Data are presented as mean ± SD (n = 3). ∗ ∗ P < 0.01 Discussion In summary, our study identified that PTL promoted the transition of macrophage phenotypes from pro-inflammatory (M1) to anti-inflammatory (M2) by modulating the TNF-α/NF-κB axis and the expression and activation of STAT3, ultimately improving the diabetic wound healing (Fig. 8). Our findings suggested that PTL might be a promising drug candidate for diabetic wound healing.Fig. 8PTL accelerates diabetic wound healing through the STAT3 and TNF-α/NF-κB pathways PTL accelerates diabetic wound healing through the STAT3 and TNF-α/NF-κB pathways The impaired wound healing observed in diabetes significantly increases the susceptibility to infection. Although the detrimental effects of dysregulated inflammatory responses on wound healing in diabetic patients have received extensive attention, the immunoregulatory mechanisms of diabetic wound healing are still poorly understood Li et al. (2024). Recently, an increasing number of studies have focused on the therapeutic application of herbal active compounds for diabetic wounds. The therapeutic potential of these active compounds in wound healing has been evidenced by their promotion of cellular proliferation and angiogenesis, coupled with inherent anti-inflammatory and antimicrobial activities Yan et al. (2025). Network pharmacology examines the pharmacological effects of drugs, clarifying the links between active compounds, molecular targets, and diseases Li et al. (2023). This methodology provides an innovative strategy for elucidating the biological mechanisms of naturally sourced molecules. Feverfew, a perennial herb with a long tradition of medicinal use, has been historically employed in the treatment of various diseases, including fever, migraine, and rheumatoid arthritis Zhan et al. (2024). From this plant, the sesquiterpene lactone compound PTL has been derived. Recent studies have demonstrated that PTL plays a positive therapeutic role in several pathologies, including colonic inflammation, autoimmune skin disorders, and diabetic retinopathy Li et al. (2025). Nevertheless, studies on the use of PTL for treating diabetic wounds remain limited. In this study, we first utilized network pharmacology analysis to predict the functional mechanism of PTL in diabetic wound healing. The analysis results showed that 218 targets in PTL were closely related to diabetic wound and involved in signaling pathways such as lipid metabolism, viral infection, and inflammatory responses. Further molecular docking analysis provided in silico evidence suggesting that PTL may contribute to diabetic wound healing, potentially through the regulation of TNF-α and STAT3. As a well‑established pro‑inflammatory cytokine, TNF-α serves a critical function in modulating immune responses. In normal wound healing, TNF-α reaches its peak level 12 to 24 h after wound formation and then returns to basal levels after the proliferative phase of wound healing Xu et al. (2013). Prolonged use of TNF-α leads to a decrease in the sensitivity of cells involved in the wound healing process to insulin stimulation, which in turn impedes the healing process. Conversely, anti-TNF-α antibody treatment in diabetic wounds enhances angiogenesis, promotes cell proliferation and migration, and ultimately facilitates wound healing (Xu et al. 2013; Goren et al. 2006). The STAT family member STAT3, located in the nucleus, regulates multiple biological processes that are critical to cellular function, including proliferation, regeneration, and immune responses Samad et al. (2020). It has been shown that STAT3 is increased in macrophages and regulates the inflammatory response by binding more strongly to histone methyltransferase SETDB2, and that the absence of STAT3 in macrophages accelerates healing of diabetic wound Mangum et al. (2024). Furthermore, p-STAT3 acts as a critical regulator in diabetic wound healing, mainly by mediating inflammatory responses Lin et al. (2025). The above analysis indicates that targeting TNF-α and STAT3 represents a potential therapeutic candidate, providing a theoretical basis for further investigation into the therapeutic effects of PTL on diabetic wounds. Subsequently, using diabetic mouse models, we found a distinct dose‑dependent effect in diabetic wound healing following PTL administration. Treatment with 100 µM and 200 µM PTL effectively accelerated diabetic wound closure, while 50 µM PTL failed to confer stable and significant therapeutic benefits. This limited response at the lowest concentration may be attributed to insufficient dosage that cannot adequately overcome the pathological barriers associated with diabetic impaired healing. Wound healing comprises an intricate, multistage process involving haemostasis, inflammation, proliferation, and tissue remodelling. In diabetic wounds, however, this process is frequently impeded by hyperglycaemia, microvascular impairment, oxidative stress, and persistent inflammation, contributing to compromised healing outcomes Cao et al. (2023). In this study, we found that PTL treatment attenuated inflammation, stimulated neovascularization, and accelerated re-epithelialization in diabetic wounds, thereby playing a critical role in the healing process. Prompted by the marked anti-inflammatory properties of PTL, we next focused on the mechanisms by which PTL modulated the inflammatory response in diabetic wounds. As a component of the innate immune system, macrophages are critical for regulating the inflammatory response in diabetic wound healing Sharifiaghdam et al. 2022; Hassanshahi et al. 2022). Macrophage phenotype transition represents a dynamic process in wound healing, characterized by the presence of two primary phenotypes within the wound microenvironment. Pro-inflammatory macrophages secrete proinflammatory molecules such as TNF-α. By the generation of ROS and release of enzymes, proinflammatory macrophages contribute to the degradation of pathogens and damaged tissue, while simultaneously initiating inflammatory responses that aid in infection clearance (Adib et al. 2025; Xu et al. 2025). Then, the pro-inflammatory macrophages (M1) convert into anti-inflammatory macrophages (M2) to reduce inflammation and enhance repair processes such as angiogenesis and extracellular matrix synthesis Jiang et al. (2024). Macrophage plasticity can drive the critical transition from the inflammatory to the proliferative phase in wound healing Kimball et al. (2019). Recent studies have shown several signaling pathways, including PI3K/AKT, PPARγ, Notch, and Toll-like receptors (TLRs), that regulate the dynamic transition between M1 and M2 macrophage phenotypes in the diabetic wound microenvironment Zhang et al. (2026). Epigenetic modifications and metabolic reprogramming also critically modulate this phenotypic switch (Song et al. 2024; Sun et al. 2026). Thus, modulating the phenotype of macrophages from a pro-inflammatory phenotype (M1) to an anti-inflammatory phenotype (M2) has emerged as a key therapeutic strategy for promoting diabetic wound healing. We found that both 100 µM and 200 µM PTL modulated the transition of macrophages from a pro-inflammatory phenotype (M1) to an anti-inflammatory phenotype (M2) in the mouse diabetic wound. In addition, treatment with either 5 µM or 10 µM PTL increased the proportion of anti-inflammatory macrophages (M2) in LPS-induced RAW264.7 cells, suggesting that PTL also promoted the transition of macrophages to an anti-inflammatory phenotype (M2) under inflammatory conditions in vitro. Therefore, our findings suggested that PTL could regulate the inflammatory response of diabetic wounds and promote wound healing by modulating the transition of macrophages into the anti-inflammatory phenotype (M2). Previous studies have shown that LPS triggers TNF-α production and exacerbates inflammatory responses in RAW264.7 cells Li et al. (2023). The level of TNF-α is elevated in diabetic patients, thereby promoting a pro-inflammatory state. It has been shown that the level of TNF-α in diabetic mouse wounds is three times higher than that in normal mouse wounds. In addition, TNF-α can enhance the inflammatory response by inducing NF-κB activation Dong et al. (2016). Under hyperglycemic conditions, TNF-α/NF-κB could amplify metabolic inflammation by upregulating the expression level of the innate immune receptor Dectin-1 in adipose tissue Al Madhoun et al. (2025). Our results similarly showed that the expressions of TNF-α and NF-κB were upregulated after LPS stimulation in RAW264.7 cells, whereas PTL could downregulate the expression levels of TNF-α and NF-κB, reducing cellular inflammatory responses. STAT3 is involved in macrophage M1 polarization, and inhibition of the STAT3 signaling pathway promotes macrophage M2 polarization, which reduces pro-inflammatory factor levels and inhibits tissue damage Sawaya et al. (2020). Our study found that the expression of STAT3 was elevated after LPS treatment, while treatment with PTL reduced the expression level of STAT3. Aberrantly expressed cytokines, hyperglycemia, and advanced glycation end products may activate STAT3 either directly or indirectly, whereas inhibiting STAT3 phosphorylation diminishes the release of proinflammatory cytokines in diabetic conditions Xuan et al. (2025). Previous study has shown that pSTAT3 expression is elevated in keratinocytes within diabetic wounds, and butyrate can downregulate pSTAT3 expression, thus interrupting the uncontrolled inflammatory cycle and facilitating wound repair in diabetes Singh et al. (2025). In our study, we found that LPS increased the expression of p-STAT3 in RAW264.7 cells, whereas PTL suppressed STAT3 activation. Our results therefore suggest that the molecular mechanism underlying PTL-mediated promotion of diabetic wound healing may involve inhibition of TNF-α/NF-κB and STAT3 activation, thereby modulating the inflammatory microenvironment in diabetic wounds. However, our study also has several limitations. Firstly, this study determined the in vitro safe concentrations of PTL through CCK‑8 experiments (2.5, 5, and 10 µM were non-toxic to macrophages, while 20 µM exhibited cytotoxicity), and in vivo screening confirmed that 100 and 200 µM PTL could promote diabetic wound healing. The rationality of PTL dosing, along with its long-term and high-dose safety, still requires validation. Additionally, the expression levels of its targets (TNF‑α and STAT3) in normal skin, the risk of off-target effects, and the effectiveness of systemic administration remain unclear, with preliminary findings suggesting that PTL may be more suitable for topical application. Besides, how PTL regulates the TNF-α/NF-κB axis and promotes the expression and activation of STAT3 needs to be further explored. In our study, only preliminary validation at the cellular level has been performed, and more in-depth analysis at the cellular level and refinement of in vivo experiments are required. In addition, molecular docking results are only predictive in silico analysis, which merely suggest potential binding affinity between PTL and the targets, rather than definitive biological evidence. The specific structural domains of PTL interacting with TNF-α and STAT3 remain to be further investigated, and experiments such as functional assays and direct binding studies need to be more rigorously refined. Finally, the relevant clinical trials of PTL are not yet conducted; we will next complete the toxicity tests and ethical procedures of PTL. Supplementary Information Below is the link to the electronic supplementary material. ESM 1(DOCX 130 KB)ESM 2(PDF 194 KB) (DOCX 130 KB) (PDF 194 KB)